StockNews.com started coverage on shares of Adverum Biotechnologies (NASDAQ:ADVM – Get Rating) in a research report released on Thursday. The firm issued a sell rating on the biotechnology company’s stock.
Separately, LADENBURG THALM/SH SH initiated coverage on shares of Adverum Biotechnologies in a research note on Tuesday, March 7th. They set a buy rating and a $2.00 price target on the stock. One research analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of Hold and an average target price of $2.75.
Adverum Biotechnologies Trading Down 11.4 %
Shares of ADVM opened at $0.75 on Thursday. The firm has a market cap of $74.90 million, a P/E ratio of -0.48 and a beta of 0.77. Adverum Biotechnologies has a 12-month low of $0.53 and a 12-month high of $1.82. The company’s 50-day moving average price is $0.70 and its 200 day moving average price is $0.78.
Insider Transactions at Adverum Biotechnologies
Institutional Investors Weigh In On Adverum Biotechnologies
Several large investors have recently modified their holdings of the company. Geode Capital Management LLC boosted its holdings in shares of Adverum Biotechnologies by 2.2% in the fourth quarter. Geode Capital Management LLC now owns 772,152 shares of the biotechnology company’s stock valued at $447,000 after acquiring an additional 16,563 shares during the period. Mirabella Financial Services LLP purchased a new stake in shares of Adverum Biotechnologies during the first quarter worth approximately $32,000. Marquette Asset Management LLC raised its stake in shares of Adverum Biotechnologies by 25.3% during the fourth quarter. Marquette Asset Management LLC now owns 121,393 shares of the biotechnology company’s stock worth $70,000 after purchasing an additional 24,483 shares during the last quarter. Rafferty Asset Management LLC raised its stake in shares of Adverum Biotechnologies by 55.9% during the second quarter. Rafferty Asset Management LLC now owns 69,954 shares of the biotechnology company’s stock worth $84,000 after purchasing an additional 25,076 shares during the last quarter. Finally, Renaissance Technologies LLC raised its stake in shares of Adverum Biotechnologies by 2.3% during the third quarter. Renaissance Technologies LLC now owns 1,118,441 shares of the biotechnology company’s stock worth $1,063,000 after purchasing an additional 25,400 shares during the last quarter. 63.68% of the stock is owned by institutional investors and hedge funds.
Adverum Biotechnologies Company Profile
Adverum Biotechnologies, Inc is a clinical-stage gene therapy company that engages in the development of gene therapies for ocular and rare diseases. The company was founded by Mark S. Blumenkranz, Thomas W. Chalberg, Jr., Mitchell H. Finer, and Steven Daniel Schwartz on July 17, 2006 and is headquartered in Redwood City, CA.
- Get a free copy of the StockNews.com research report on Adverum Biotechnologies (ADVM)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for Adverum Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adverum Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.